EFFECTS OF EMODIN ON CLINICAL EFFICACY, PEPSINOGEN PGI, PGII AND TUMOR MARKER CA724 IN PATIENTS WITH GASTRIC CANCER

Jun Li, Liujie Gao, Jiyuan Ding, Wanzhen Zheng^*

Hangzhou Cancer Hospital, No.1 Cancer Ward of Traditional Chinese and Western Medicine, Hangzhou, Zhejiang, 310002, China

Objective: To explore the effect of emodin on the clinical efficacy, pepsinogen I (PGI), pepsinogen II (PGII), and tumor marker carbohydrate antigen 724 (CA724) in patients with gastric cancer. 

Methods: Sixty-eight patients with gastric cancer treated in the oncology department of our hospital from February 2018 to March 2020 were randomly selected and divided into a study group and a control group, with 34 cases in each group. The control group was treated with cisplatin and capecitabine, and the study group was given emodin on the basis of the control group. Both groups were treated for 3 weeks. The basic clinical data, clinical effects, PGI, PGII, CA724, and adverse reactions were compared between the two groups. 

Results: The total effective rates of the study group and the control group were 91.18% and 70.59%, respectively. The study group was significantly higher than the control group (P < 0.05). Compared with the before treatment and after treatment, the levels of PGI, PGII, and CA724 in the two groups were significantly increased, while the levels of PGII and CA724 were significantly decreased. The changes of each index in the study group were statistically significant (P<0.05). The main adverse reactions were gastrointestinal reactions, myelosuppression, thrombocytopenia, and leucopenia. Among them, the incidence of adverse reactions in the study group and the control group was 11.76% and 35.29%, respectively. The study group was significantly lower than that in the control group (P<0.05). 

Conclusion: Emodin in the treatment of gastric cancer can significantly reduce the levels of PGI and CA724 and improve the level of PGII, with significant clinical efficacy and higher safety.